Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Vasectomy Alternative: Male Contraceptive Gel Proves Effective in Animal Models

XTALKS VITALS NEWS

Male Contraceptive

While some pharmaceutical companies have tried in the past to develop a male contraceptive, so far none has been successful at making a safe and effective male birth control.

Share this!

February 13, 2017 | by Sarah Hand, M.Sc.

From birth control pills and injections, to intrauterine devices (IUDs), women have the benefit of being able to choose from a wide range of contraceptives. While some pharmaceutical companies have tried in the past to develop a male contraceptive, so far none has been successful at making a safe and effective male birth control.

As the Centers for Disease Control and Prevention (CDC) estimates that nearly half of all pregnancies are unplanned, there is a clear need for additional forms of contraception. Now, a company known as Revolution Contraceptives have developed a male non-hormonal contraceptive gel, named Vasalgel.

Last year, researchers tested Vasalgel in rabbits, and found that the product could rival vasectomies in terms of its successfulness as a long-term male contraceptive. A recent study – published in the journal, Basic and Clinical Andrology – tested the drug in monkeys and found similarly promising results.

Vasalgel is a high molecular weight polymer, which could offer a reversible contraceptive option for men. The drug is injected into the tube which carries sperm from the testicles to the urethra – known as the vas deferens – where it forms a resistant barrier to prevent the ejaculation of sperm.



To test the safety and effectiveness of Vasalgel, the drug was injected into 16 adult male rhesus monkeys, and the results were compared to the same number of monkeys who were previously vasectomized. After recovering from the procedure, the animals were returned to group housing facilities where they cohabitated with females for a breeding period of six months to two years.

Offspring resulting from this cohabitation were tested for paternity based on genetic testing of blood samples. None of the males treated with Vasalgel injections had any offspring.

The researchers reported that the Vasalgel injection was found to be relatively safe, resulting in only a few complications. For example, one monkey developed a buildup of sperm in the vas deferens – known as a sperm granuloma – which is also a common complication of vasectomies.

“Our research shows that Vasalgel placement into the vas deferens produces reliable contraception in mature male rhesus monkeys as shown by the lack of pregnancies in reproductively viable females with which the males were housed,” said Dr. Catherine VandeVoort, senior author of the study and researcher at the California National Primate Research Centre. “Importantly, we show that the method of Vasalgel placement is safe and produced fewer complications than usually occur with a vasectomy.”


Keywords: Male Contraceptive, Animal Models, Preclinical


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New Self-Injectable Form of Lupus Drug Approved by the FDA

July 25, 2017 - Patients with systemic lupus erythematosus (SLE) will now have the option to self-inject their medication thanks to the FDA approval of GSK’s reformulated lupus drug, Benlysta (belimumab).

Featured In: Biotech News


Canadian Chicken Farmers to Further Reduce Use of Antibiotics

July 24, 2017 - The Chicken Farmers of Canada, a national group dedicated to supporting poultry farmers and helping them meet consumer demand for chicken, has announced their strategy for eliminating the use of certain antimicrobials in meat production.

Featured In: Food News


Neonatal MRI Medical Device Approved by the FDA

July 24, 2017 - Medical device maker Aspect Imaging has received US Food and Drug Administration (FDA) approval for its Embrace Neonatal MRI System.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets from #AAIC17

REGISTER FOR THESE WEBINARS

Into the Great Wide Open: PTC’s Transformation & Global Journey to Bring Patients a First Ever Rare Disease Therapy


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.